Sublingual Immunotherapy in Patients With Atopic Dermatitis

Inclusion Criteria: * Patients of either sex ,aged from 18 to 60 years. Diagnosed of atopic dermatitis. * Mild to moderate AD ( \[SCORAD\] 1O-40) * The results of skin prick tests with dermatophagoides farinae allergen extracts preparation is positive(≥2+) * Written informed consent by the subject or legal guardian. * Female patients of child-bearing potential must be negative pregnant test on screening and use an appropriate method of contraception. Exclusion Criteria: * Dust mites are not the primary allergens. * Pregnant, breastfeeding women or women planned to pregnant within 1 year. * Have concurrent skin disease that it could interfere with the study evaluation. * Were treated with antihistamines or topical therapy within 7 days of randomization. * Have received systemic corticosteroids,leukotriene receptor antagonists or immunosuppressants within 4 weeks of randomization. * Have received phototherapy (e.g. UVA, UVB) within 4 weeks of randomization. * Have a history of immune suppressed diseases(malignant tumor or infection of HIV), autoimmune disease or tuberculosis. * Patients with impaired liver function (aspartate aminotransferase and/ or alanine aminotransferase levels 1.5 times the upper limit of normal), impaired renal function(serum creatinine\>normal value) or other severe diseases. * Bronchial asthma patients who need treatments with corticosteroids and or β agonists(including injection, oral administration or inhalation) regularly. * Patients who need to take β-blockers during research. * Have received investigational drugs within 3 months prior to randomization or planned use of other investigational drugs during participation in this study. * Have received immunotherapy with dust mite preparation within 3 years prior to randomization. * Patients with severe mental disorders.